Literature DB >> 8575195

The role of CD4 in HIV envelope-mediated pathogenesis.

R F Siliciano1.   

Abstract

There is now compelling evidence that env-CD4 interactions are central to several complex pathogenic mechanisms in HIV-1 infection. In addition to mediating virus attachment to CD4+ cells, the high affinity interaction of env protein with CD4 is also important in initiating both syncytium formation and syncytium-independent cytopathic effects. In addition, shed gp120 can bind to CD4 on noninfected cells and interfere with the function of these cells while at the same time rendering the cells susceptible to destruction by ADCC, by CD4+ CTLs or by programmed cell death induced by cross-linking of CD4 with gp120 and anti-gp120 followed by cellular activation. Although all of these mechanisms have been demonstrated to operate in vitro, it remains unclear how important each mechanism is in vivo. Nevertheless, the central role of env-CD4 interactions in all of these pathogenic mechanisms highlights the importance of developing effective low molecular weight inhibitors of this reaction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8575195     DOI: 10.1007/978-3-642-79798-9_8

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  16 in total

1.  HIV-1 envelope induces activation of caspase-3 and cleavage of focal adhesion kinase in primary human CD4(+) T cells.

Authors:  C Cicala; J Arthos; A Rubbert; S Selig; K Wildt; O J Cohen; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  The human immunodeficiency virus type 1 tat protein enhances Cryptosporidium parvum-induced apoptosis in cholangiocytes via a Fas ligand-dependent mechanism.

Authors:  Steven P O'Hara; Aaron J Small; Jeremy B Nelson; Andrew D Badley; Xian-Ming Chen; Gregory J Gores; Nicholas F Larusso
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

Review 3.  Antibodies as defensive enzymes.

Authors:  Sudhir Paul; Yasuhiro Nishiyama; Stephanie Planque; Sangeeta Karle; Hiroaki Taguchi; Carl Hanson; Marc E Weksler
Journal:  Springer Semin Immunopathol       Date:  2005-01-05

4.  Avian sarcoma and leukosis virus cytopathic effect in the absence of TVB death domain signaling.

Authors:  Sara Klucking; Asha S Collins; John A T Young
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  High major histocompatibility complex-unrestricted lysis of simian immunodeficiency virus envelope-expressing cells predisposes macaques to rapid AIDS progression.

Authors:  C Yin; M S Wu; C D Pauza; M S Salvato
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  An NF-kappa B-dependent survival pathway protects against cell death induced by TVB receptors for avian leukosis viruses.

Authors:  Yuling Chi; Felipe Diaz-Griffero; Chenguang Wang; John A T Young; Jürgen Brojatsch
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

7.  Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs.

Authors:  Julià Blanco; Imma Clotet-Codina; Berta Bosch; Mercedes Armand-Ugón; Bonaventura Clotet; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 8.  Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it?

Authors:  A Boasso; G M Shearer; C Chougnet
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

9.  HIV-1 Tat protein suppresses cholangiocyte toll-like receptor 4 expression and defense against Cryptosporidium parvum.

Authors:  Steven P O'Hara; Aaron J Small; Gabriella B Gajdos; Andrew D Badley; Xian-Ming Chen; Nicholas F Larusso
Journal:  J Infect Dis       Date:  2009-04-15       Impact factor: 5.226

Review 10.  Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART.

Authors:  E A Berger; B Moss; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.